top of page
Asian Institute of Research, Journal Publication, Journal Academics, Education Journal, Asian Institute
Asian Institute of Research, Journal Publication, Journal Academics, Education Journal, Asian Institute

Journal of Health and Medical Sciences

ISSN 2622-7258

Screen Shot 2018-08-12 at 1.24.09 AM.png
Screen Shot 2018-08-12 at 1.24.02 AM.png
Screen Shot 2018-08-12 at 1.23.57 AM.png
Screen Shot 2018-08-12 at 1.23.52 AM.png
open access

Published: 18 May 2024

Reactogenicity of Primary Vaccination with Hexavalent Vaccines in Infants: Mathematical Projections in Four Southeast Asian Countries

Ahmed Mohy, Deliana Permatasari, Johan Wijoyo, Chanida Kwanthitinan, Jittakarn Mitisubin, Thanabalan Fonseka, Marina George

GSK, Hari Group Limited

journal of social and political sciences
pdf download

Download Full-Text Pdf



Pages: 51-63

Keywords: Hexavalent Vaccine, Adverse Events, Reactogenicity, Indonesia, Malaysia, Philippines, Thailand


Hexavalent vaccines against diphtheria (D), tetanus (T), pertussis (P), hepatitis B (HBV), polio (IPV) and Haemophilus influenzae b (Hib) are established in the immunization of infants in many countries. A meta-analysis of results from six head-to-head clinical trials comparing two hexavalent vaccines reported that the rate of three local (redness, pain and swelling at the injection site) and five systemic (fever, drowsiness, persistent crying, irritability and anorexia) adverse reactions was lower for the DT3aP-HBV-IPV/Hib vaccine than for the DT2aP-HBV-IPV-Hib vaccine. The objective of this analysis was to compare the impact of adverse reactions after a single dose of the primary series of DT3aP-HBV-IPV/Hib vaccine versus DT2aP-HBV-IPV-Hib vaccine in the infant populations of four countries in Southeast Asia (Indonesia, Malaysia, the Philippines and Thailand). A previously published mathematical projection tool was combined with published data to estimate the number of adverse reactions potentially avoided in 2023 by using DT3aP-HBV-IPV/Hib vaccine compared with DT2aP-HBV-IPV-Hib vaccine. The results indicated that for every 100 infants vaccinated, using DT3aP-HBV-IPV/Hib instead of DT2aP-HBV-IPV-Hib would be expected to avoid adverse reactions, ranging from 3 events of swelling at the injection site to 10 events of fever. In 2023, over 280,000 solicited local and systemic adverse reactions of any grade could have been avoided in Indonesia, over 200,000 in Malaysia, over 80,000 in Thailand and over 158,000 in the Philippines. These results could be useful to healthcare decision-makers considering immunization strategies in Southeast Asia.


  1. Aps, L., Piantola, M. A. F., Pereira, S. A., Castro, J. T., Santos, F. A. O., & Ferreira, L. C. S. (2018). Adverse events of vaccines and the consequences of non-vaccination: a critical review. Revista Saude Publica, 52, 40.

  2. Barnighausen, T., Bloom, D. E., Canning, D., Friedman, A., Levine, O. S., O'Brien, J., Privor-Dumm, L., & Walker, D. (2011). Rethinking the benefits and costs of childhood vaccination: the example of the Haemophilus influenzae type b vaccine. Vaccine, 29(13), 2371-2380.

  3. Bayliss, J., Nissen, M., Prakash, D., Richmond, P., Oh, K. B., & Nolan, T. (2021). Control of vaccine preventable diseases in Australian infants: reviewing a decade of experience with DTPa-HBV-IPV/Hib vaccine. Human Vaccines & Immunotherapeutics, 17(1), 176-190.

  4. Betsch, C., Bodeker, B., Schmid, P., & Wichmann, O. (2018). How baby's first shot determines the development of maternal attitudes towards vaccination. Vaccine,36(21), 3018-3026.

  5. Carabin, H., Edmunds, W. J., Kou, U., van den Hof, S., & Nguyen, V. H. (2002). The average cost of measles cases and adverse events following vaccination in industrialised countries. BMC Public Health, 2, 22.

  6. Centers for Disease Control Prevention. (2011). Ten great public health achievements--worldwide, 2001-2010. Morbidity and Mortality Weekly Report, 60(24), 814-818.

  7. Coe, M., Gergen, J., & Vilcu, I. (2017). “Philippines Country Brief”. Sustainable Immunization Financing in Asia Pacific. Retrieved 9 June 2023 from

  8. European Medicines Agency. (2021a). Hexaxim. Retrieved 4 January 2021 from

  9. European Medicines Agency. (2021b). Infanrix Hexa. Retrieved 4 January 2021 from

  10. European Medicines Agency. (2021c). Vaxelis. Retrieved 4 January 2021 from

  11. George, M., Perez Martin, J., AbdelGhany, M., Gkalapi, F., Jamet, N., Kosse, R. C., Ruiz Garcia, Y., Turriani, E., & Berlaimont, V. (2023). Reduced reactogenicity of primary vaccination with DT3aP-HBV-IPV/Hib compared with DT2aP-HBV-IPV-Hib among infants: Mathematical projections in six countries. Human Vaccines & Immunotherapeutics, 19(1), 2202124.

  12. Knuf, M., Haas, H., Garcia-Corbeira, P., Turriani, E., Mukherjee, P., Janssens, W., & Berlaimont, V. (2021). Hexavalent vaccines: What can we learn from head-to-head studies? Vaccine, 39(41), 6025-6036.

  13. Koslap-Petraco, M. B., & Judelsohn, R. G. (2008). Societal impact of combination vaccines: experiences of physicians, nurses, and parents. Journal of Pediatric Health Care, 22(5), 300-309.

  14. Masadeh, M. M., Alzoubi, K. H., Al-Azzam, S. I., Al-Agedi, H. S., Abu Rashid, B. E., & Mukattash, T. L. (2014). Public awareness regarding children vaccination in Jordan. Human Vaccines & Immunotherapeutics, 10(6), 1762-1766.

  15. Mukherjee, P., Akpo, E. I. H., Kuznetsova, A., Knuf, M., Silfverdal, S. A., Kosalaraksa, P., & Mihalyi, A. (2021). Hexavalent vaccines in infants: a systematic literature review and meta-analysis of the solicited local and systemic adverse reactions of two hexavalent vaccines. Expert Review of Vaccines, 20(3), 319-330.

  16. Obando-Pacheco, P., Rivero-Calle, I., Gomez-Rial, J., Rodriguez-Tenreiro Sanchez, C., & Martinon-Torres, F. (2018). New perspectives for hexavalent vaccines. Vaccine, 36(36), 5485-5494.

  17. Rosso, A., Massimi, A., Pitini, E., Nardi, A., Baccolini, V., Marzuillo, C., De Vito, C., & Villari, P. (2020). Factors affecting the vaccination choices of pregnant women for their children: a systematic review of the literature. Human Vaccines & Immunotherapeutics, 16(8), 1969-1980.

  18. Skibinski, D. A., Baudner, B. C., Singh, M., & O'Hagan, D. T. (2011). Combination vaccines. Journal of Global Infectious Diseases, 3(1), 63-72.

  19. Smith, L. E., Amlot, R., Weinman, J., Yiend, J., & Rubin, G. J. (2017). A systematic review of factors affecting vaccine uptake in young children. Vaccine, 35(45), 6059-6069.

  20. United Nations Department of Economic and Social Affairs Population Division. (2022). World Population Prospects 2022, Online Edition.

  21. World Health Organization. Diphtheria tetanus toxoid and pertussis (DTP) vaccination coverage. Retrieved 9 June 2023 from

bottom of page